Cencora earnings release, August 5, 2026

Cencora, Inc. (COR) · Form 8-K, Item 2.02 · Filed · SEC filing

CENCORA REPORTS FISCAL 2026 THIRD QUARTER RESULTS

Revenue of $84.8 billion for the Third Quarter, a 5.1 percent Increase Year-Over-Year

Third Quarter GAAP Diluted EPS of $3.94 and Adjusted Diluted EPS of $4.48

Adjusted Diluted EPS Guidance Range Raised to $17.75 to $17.95 for Fiscal 2026

Cencora Repurchased $1 Billion of Shares in the Third Fiscal Quarter

CONSHOHOCKEN, PA, August 5, 2026

-

Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 third quarter ended June 30, 2026, revenue increased

5.1 percent year-over-year to $84.8 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.94 for the third quarter of fiscal 2026 compared to $3.52 in the prior year third quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased 12.0 percent to $4.48 in the fiscal third quarter from $4.00 in the prior year third quarter.

Cencora is updating its outlook for fiscal year 2026. The Company does not provide forward-looking guidance on a GAAP basis as discussed below in Fiscal Year 2026 Guidance. Adjusted diluted EPS guidance has been raised from the previous range of $17.70 to $17.90 to a range of $17.75 to $17.95.

“Our third quarter results reflect the power of our pharmaceutical-centric strategy and the continued execution of our team members. Our strong performance and confidence in our outlook enabled us to raise our fiscal 2026 guidance, underscoring the value we deliver for our stakeholders,” said Robert P. Mauch, President and Chief Executive Officer of Cencora.

“Our investments in specialty, digital transformation and talent are strengthening our ability to support our customers across the healthcare ecosystem while positioning Cencora for sustainable long-term growth. The capabilities we have built, and the strength of our core businesses provide a solid foundation for continued growth as we close fiscal 2026,” Mr. Mauch continued.¹

Third Quarter Fiscal Year 2026 Summary Results

Below, Cencora presents descriptive summaries of the Company’s GAAP and adjusted (non-GAAP) quarterly results. In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. For more information related to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the “Supplemental Information Regarding Non-GAAP Financial Measures” following the tables.

Third Quarter GAAP Results

• Revenue:

In the third quarter of fiscal 2026, revenue was $84.8 billion, up 5.1 percent compared to the same quarter in the previous fiscal year, primarily due to a 4.9 percent increase in revenue within the U.S. Healthcare Solutions segment and a 5.9 percent increase in revenue within the International Healthcare Solutions segment.

• Gross Profit:

Gross profit in the third quarter of fiscal 2026 was $3.6 billion, a 24.1 percent increase compared to the same quarter in the previous fiscal year, primarily due to the increases in gross profit in both reportable segments and a higher LIFO credit in the current year quarter. Gross profit as a percentage of revenue was 4.26 percent, an increase of 66 basis points from the prior year quarter primarily due to the increase in U.S. Healthcare Solutions’ gross profit margin as a result of the February 2026 acquisition of OneOncology, offset in part by increased sales of GLP-1s, which have lower gross profit margins.

• Operating Expenses:

In the third quarter of fiscal 2026, operating expenses were $2.5 billion, a 21.9 percent increase compared to the same quarter in the previous fiscal year. This increase was primarily driven by higher expenses as a result of the February 2026 acquisition of OneOncology. Operating expense growth was offset in part by a $102.0 million reduction of opioid liability related to the dismissal of opioid litigation.

• Operating Income:

In the third quarter of fiscal 2026, operating income was $1.1 billion, an increase of 29.1 percent compared to the same quarter in the previous fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses. Operating income as a percentage of revenue was 1.32 percent in the third quarter of fiscal 2026, an increase of 24 basis points from the prior year quarter.

• Interest Expense, Net:

In the third quarter of fiscal 2026, net interest expense was $140.7 million, an increase of $58.9 million from the prior year quarter primarily due to an increase in interest expense as a result of our issuance of senior notes and variable-rate term loans to finance a portion of the February 2026 acquisition of OneOncology and a decrease in interest income.

• Effective Tax Rate:

The effective tax rate was 22.1 percent for the third quarter of fiscal 2026 compared to 23.0 percent in the prior year quarter.

• Diluted Earnings Per Share:

Diluted earnings per share was $3.94 in the third quarter of fiscal 2026, an 11.9 percent increase compared to $3.52 in the previous fiscal year’s third quarter.

• Diluted Shares Outstanding:

Diluted weighted average shares outstanding for the third quarter of fiscal 2026 were 193.9 million, a decrease of 0.7 percent versus the prior year third quarter as a result of opportunistic share repurchases.²

Third Quarter Adjusted (non-GAAP) Results

• Revenue:

No adjustments were made to the GAAP presentation of revenue. In the third quarter of fiscal 2026, revenue was $84.8 billion, up 5.1 percent compared to the same quarter in the previous fiscal year, primarily due to a 4.9 percent increase in revenue within the U.S. Healthcare Solutions segment and a 5.9 percent increase in revenue within the International Healthcare Solutions segment.

• Adjusted Gross Profit:... (truncated)gross profit in both reportable segments. Adjusted gross profit as a percentage of revenue was 4.16 percent in the fiscal 2026 third quarter, an increase of 61 basis points from the prior year quarter primarily due to the increase in U.S. Healthcare Solutions’ gross profit margin as a result of the February 2026 acquisition of OneOncology, offset in part by increased sales of GLP-1s, which have lower gross profit margins.

• Adjusted Operating Expenses:

In the third quarter of fiscal 2026, adjusted operating expenses were $2.3 billion, a 26.8 percent increase compared to the same quarter in the previous fiscal year, primarily driven by higher expenses as a result of the February 2026 acquisition of OneOncology.

• Adjusted Operating Income:

In the third quarter of fiscal 2026, adjusted operating income was $1.2 billion, a 17.0 percent increase compared to the same quarter in the prior fiscal year due to the increase in gross profit, offset in part by the increase in operating expenses. Adjusted operating income as a percentage of revenue was 1.46 percent in the fiscal 2026 third quarter, an increase of 15 basis points when compared to the prior year quarter.

• Interest Expense, Net:

No adjustments were made to the GAAP presentation of net interest expense. In the third quarter of fiscal 2026, net interest expense was $140.7 million, an increase of $58.9 million from the prior year quarter primarily due to an increase in interest expense as a result of our issuance of senior notes and variable-rate term loans to finance a portion of the February 2026 acquisition of OneOncology and a decrease in interest income.

• Adjusted Effective Tax Rate:

The adjusted effective tax rate was 19.9 percent for the third quarter of fiscal 2026 compared to 20.7 percent in the prior year quarter.

• Adjusted Diluted Earnings Per Share:

Adjusted diluted earnings per share was $4.48 in the third quarter of fiscal 2026, a 12.0 percent increase compared to $4.00 in the previous fiscal year’s third quarter.

• Diluted Shares Outstanding:

No adjustments were made to the GAAP presentation of diluted shares outstanding. Diluted weighted average shares outstanding for the third quarter of fiscal 2026 were 193.9 million, a decrease of 0.7 percent versus the prior year third quarter as a result of opportunistic share repurchases.

Segment Discussion

The Company is organized geographically based upon the products and services it provides to its customers under two reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions. Additionally, other businesses for which the Company is exploring strategic alternatives have been grouped together in Other. These businesses include MWI Animal Health, Profarma, U.S. Consulting Services (which was divested in April 2026), and certain components of PharmaLex.

U.S. Healthcare Solutions Segment

U.S. Healthcare Solutions revenue was $74.9 billion in the third quarter of fiscal 2026, an increase of 4.9 percent compared to the same quarter of the previous fiscal year primarily due to overall market growth largely driven by unit volume growth, including increased sales of specialty products to health systems and physician practices and products labeled for diabetes and/or weight loss in the GLP-1 class. The revenue growth was offset in part by a decline in manufacturer prices related to certain brand pharmaceutical products, the 2025 loss of an oncology customer, and lower sales to our large mail order customer, as expected and consistent with our second quarter. Segment operating income of $966.2 million in the third quarter of fiscal 2026 was up 15.9 percent compared to the same quarter in the previous fiscal year due to the increase in gross profit, as a result of the February 2026 acquisition of OneOncology and increased pharmaceutical sales, offset in part by the increase in operating expenses and the 2025 loss of an oncology customer.³

International Healthcare Solutions Segment

International Healthcare Solutions revenue was $7.7 billion in the third quarter of fiscal 2026, an increase of 5.9 percent compared to the previous fiscal year’s third quarter primarily due to growth in our European distribution business and our global specialty logistics business. Segment operating income in the third quarter of fiscal 2026 was $165.9 million, an increase of 20.8 percent, primarily due to increased operating income at our European distribution business and our global specialty logistics business. On a constant currency basis, International Healthcare Solutions revenue increased by 6.1 percent in the third quarter of fiscal 2026 compared to the previous fiscal year’s third quarter, while segment operating income increased by 23.1 percent.

Other

Revenue in Other was $2.3 billion in the third quarter of fiscal 2026, an increase of 6.9 percent compared to the previous fiscal year’s third quarter due to growth at Profarma and MWI Animal Health, offset in part by a decrease in sales at our consulting services businesses due to the April 2026 divestiture of U.S. Consulting Services. Operating income in Other in the third quarter of fiscal 2026 was $108.7 million, an increase of 24.8 percent, primarily due to an increase in operating income at MWI Animal Health due to business growth and, to a lesser extent, a decline in depreciation expense resulting from its classification as held for sale.

Recent Company Highlights & Milestones

• Good Neighbor Pharmacy, a national franchise for independent pharmacies offered through Cencora, announced that it has been ranked “#1 in Customer Satisfaction with Chain Drug Store Pharmacies” in the J.D. Power 2026 U.S. Pharmacy Study. This is the fourteenth time that Good Neighbor Pharmacy has earned this recognition.

• Cencora announced the appointment of Eva Boratto to its Enterprise Leadership Team as Executive Vice President & Chief Financial Officer.

• ... (truncated)rprise Leadership Team as Executive Vice President & Chief Human Resources Officer.

Fiscal Year 2026 Guidance on an Adjusted (non-GAAP) Basis

Cencora is now updating its fiscal year 2026 financial guidance to reflect the Company’s expectations for continued strong full year performance and opportunistic share repurchases completed in the third quarter. In the quarter, the Company opportunistically repurchased $1 billion of shares, which is the amount that the Company previously expected to complete by the end of calendar 2026.

Financial statements

Income Statement

Third Quarter Fiscal Year 2026 Summary Results

GAAPAdjusted (Non-GAAP)
Revenue$84.8B$84.8B
Gross Profit$3.6B$3.5B
Operating Expenses$2.5B$2.3B
Operating Income$1.1B$1.2B
Interest Expense, Net$141M$141M
Effective Tax Rate22.1%19.9%
Net Income Attributable to Cencora, Inc.$764M$869M
Diluted Earnings Per Share3.944.48
Diluted Shares Outstanding193.9M193.9M

Income Statement

2026 Guidance(1)

2026 Guidance(1)Fiscal 2025 Actuals
Revenue4% to 6% growth$321.3B
U.S. Healthcare Solutions Segment(2)4% to 6% growth$285.0B
International Healthcare Solutions Segment(2)(3)~8% growth$28.3B
Other(2)~6% growth$8.2B
Adjusted operating income13% to 14% growth$4.2B
U.S. Healthcare Solutions Segment(2)14.5% to 15.5% growth$3.3B
International Healthcare Solutions Segment(2)(3)~9% growth$588M
Other(2)~10% growth$352M
Adjusted diluted earnings per share$17.75 to $17.9516
Net interest expense~$490M$292M
Adjusted effective tax rate~20%20.6%
Diluted weighted average shares outstanding~194M195.2M
Adjusted free cash flow~$3.0B$3.0B
Capital expenditures~$900M$668M

Income Statement

Three Months Ended June 30, 2026 — (unaudited)

Three Months Ended June 30, 2026% of RevenueThree Months Ended June 30, 2025% of Revenue% Change
Revenue84,754,83780,663,5325.1%
Cost of goods sold 181,147,60277,756,4174.4%
Gross profit3,607,2354.26%2,907,1153.6%24.1%
Operating expenses:Distribution, selling, and administrative2,132,4652.52%1,672,8812.07%27.5%
Operating expenses:Depreciation and amortization269,4990.32%253,9950.31%6.1%
Operating expenses:Litigation and opioid-related (credit) expenses, net 2-88,64317,974
Operating expenses:Acquisition and divestiture-related deal and integration expenses 3113,06952,838
Operating expenses:Restructuring and other expenses60,62841,773
Operating expenses:Total operating expenses2,487,0182.93%2,039,4612.53%21.9%
Operating expenses:Operating income1,120,2171.32%867,6541.08%29.1%
Operating expenses:Other income, net 4-16,882-110,417
Operating expenses:Interest expense, net140,70581,79472.0%
Operating expenses:Income before income taxes996,3941.18%896,2771.11%11.2%
Operating expenses:Income tax expense219,727206,528
Operating expenses:Net income776,6670.92%689,7490.86%12.6%
Operating expenses:Net income attributable to noncontrolling interests-13,149-2,347
Operating expenses:Net income attributable to Cencora, Inc.763,5180.9%687,4020.85%11.1%
Earnings per share:Basic3.953.5511.3%
Earnings per share:Diluted3.943.5211.9%
Weighted average common shares outstanding:Basic193,147193,822-0.3%
Weighted average common shares outstanding:Diluted193,944195,230-0.7%

Income Statement

Nine Months Ended June 30, 2026 — (unaudited)

Nine Months Ended June 30, 2026% of RevenueNine Months Ended June 30, 2025% of Revenue% Change
Revenue249,042,769237,604,2654.8%
Cost of goods sold 1238,775,124229,079,3034.2%
Gross profit10,267,6454.12%8,524,9623.59%20.4%
Operating expenses:Distribution, selling, and administrative5,905,3132.37%4,744,9762.0%24.5%
Operating expenses:Depreciation and amortization779,1920.31%792,3050.33%-1.7%
Operating expenses:Litigation and opioid-related (credit) expenses, net 2-160,93646,263
Operating expenses:Acquisition and divestiture-related deal and integration expenses 3355,652190,930
Operating expenses:Restructuring and other expenses, net115,667140,390
Operating expenses:Impairment of assets, including goodwill 4249,498
Operating expenses:Total operating expenses7,244,3862.91%5,914,8642.49%22.5%
Operating expenses:Operating income3,023,2591.21%2,610,0981.1%15.8%
Operating expenses:Other income, net 5-1,123,921-48,997
Operating expenses:Interest expense, net353,574213,71565.4%
Operating expenses:Income before income taxes3,793,6061.52%2,445,3801.03%55.1%
Operating expenses:Income tax expense821,285544,495
Operating expenses:Net income2,972,3211.19%1,900,8850.8%56.4%
Operating expenses:Net income attributable to noncontrolling interests-7,824-7,012
Operating expenses:Net income attributable to Cencora, Inc.2,964,4971.19%1,893,8730.8%56.5%
Earnings per share:Basic15.289.7756.4%
Earnings per share:Diluted15.219.756.8%
Weighted average common shares outstanding:Basic193,971193,7940.1%
Weighted average common shares outstanding:Diluted194,883195,172-0.1%

Income Statement

Percentages of Revenue: — (unaudited)

GAAPAdjusted Non-GAAP
Gross profit4.26%4.16%
Operating expenses2.93%2.7%
Operating income1.32%1.46%

Income Statement

Three Months Ended June 30, 2025 — (unaudited)

Three Months Ended June 30, 2025 – Gross ProfitThree Months Ended June 30, 2025 – Operating ExpensesThree Months Ended June 30, 2025 – Operating IncomeThree Months Ended June 30, 2025 – Income Before Income TaxesThree Months Ended June 30, 2025 – Income Tax ExpenseThree Months Ended June 30, 2025 – Net Income Attributable to CencoraThree Months Ended June 30, 2025 – Diluted Earnings Per Share
GAAP2,907,1152,039,461867,654896,277206,528687,4023.52
Gains from antitrust litigation settlements-9,495-9,495-9,4957,668-17,163-0.09
LIFO credit-52,058-52,058-52,058-13,377-38,681-0.2
Türkiye highly inflationary impact14,77614,77616,79916,7990.09
Acquisition-related intangibles amortization-124,869124,869124,86915,241108,8480.56
Litigation and opioid-related expenses-17,97417,97417,9742,86815,1060.08
Acquisition and divestiture-related deal and integration expenses-52,83852,83852,838-94453,7820.28
Restructuring and other expenses-41,77341,77341,7735,20336,5700.19
Gain on equity method investment 1-39,718-39,718-0.2
Other, net-34,007-6,633-27,374-0.14
Tax reform 2-26,006-11,780-14,226-0.07
Adjusted Non-GAAP2,860,3381,802,0071,058,331989,246204,774781,3454

Income Statement

Percentages of Revenue: — (unaudited)

GAAPAdjusted Non-GAAP
Gross profit3.6%3.55%
Operating expenses2.53%2.23%
Operating income1.08%1.31%

Income Statement

Nine Months Ended June 30, 2026 — (unaudited)

Nine Months Ended June 30, 2026 – Gross ProfitNine Months Ended June 30, 2026 – Gross ProfitNine Months Ended June 30, 2026 – Operating ExpensesNine Months Ended June 30, 2026 – Operating ExpensesNine Months Ended June 30, 2026 – Operating IncomeNine Months Ended June 30, 2026 – Operating IncomeNine Months Ended June 30, 2026 – Income Before Income TaxesNine Months Ended June 30, 2026 – Income Before Income TaxesNine Months Ended June 30, 2026 – Income Tax ExpenseNine Months Ended June 30, 2026 – Income Tax ExpenseNine Months Ended June 30, 2026 – Net Income Attributable to CencoraNine Months Ended June 30, 2026 – Net Income Attributable to CencoraNine Months Ended June 30, 2026 – Diluted Earnings Per Share
GAAP10,267,6457,244,3863,023,2593,793,606821,2852,964,49715.21
Gains from antitrust litigation settlements-34,184-34,184-34,184-9,740-24,444-0.13
LIFO credit-381,896-381,896-381,896-90,615-291,281-1.49
Türkiye highly inflationary impact38,44738,44734,92134,9210.18
Acquisition-related intangibles amortization-358,642358,642358,642102,191254,3011.3
Litigation and opioid-related credit, net 1160,936-160,936-160,936-36,010-124,926-0.64
Acquisition and divestiture-related deal and integration expenses-355,652355,652355,65239,727315,9251.62
Restructuring and other expenses, net-115,667115,667115,66736,59679,0710.41
Impairment of assets, including goodwill 2-249,498249,498249,49849,989199,5091.02
Remeasurement gain related to OneOncology acquisition 3-1,086,612-252,460-834,152-4.28
Other, net-8,170-2,557-5,613-0.03
Tax reform 4-10,093-36,96326,8700.14
Adjusted Non-GAAP9,890,0126,325,8633,564,1493,226,095621,4432,594,67813.31
Adjusted Non-GAAP % change vs. prior year19%23.8%11.4%7.7%1.1%9.4%9.5

Income Statement

Percentages of Revenue: — (unaudited)

GAAPAdjusted Non-GAAP
Gross profit4.12%3.97%
Operating expenses2.91%2.54%
Operating income1.21%1.43%

Income Statement

Percentages of Revenue: — (unaudited)

GAAPAdjusted Non-GAAP
Gross profit3.59%3.5%
Operating expenses2.49%2.15%
Operating income1.1%1.35%

Income Statement

Three Months Ended June 30, — (unaudited)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Three Months Ended June 30, – % Change
U.S. Healthcare Solutions966,178833,65015.9%
International Healthcare Solutions165,852137,27520.8%
Other108,73687,10424.8%
Intersegment eliminations-2,680302
Total segment operating income1,238,0861,058,33117.0%
Gains from antitrust litigation settlements5,4949,495
LIFO credit94,30452,058
Türkiye highly inflationary impact-15,405-14,776
Acquisition-related intangibles amortization-117,208-124,869
Litigation and opioid-related credit (expenses), net88,643-17,974
Acquisition and divestiture-related deal and integration expenses-113,069-52,838
Restructuring and other expenses-60,628-41,773
Operating income1,120,217867,65429.1%
U.S. Healthcare SolutionsGross profit3.17%2.54%
U.S. Healthcare SolutionsOperating expenses1.88%1.37%
U.S. Healthcare SolutionsOperating income1.29%1.17%
International Healthcare SolutionsGross profit10.7%10.14%
International Healthcare SolutionsOperating expenses8.54%8.25%
International Healthcare SolutionsOperating income2.16%1.89%
OtherGross profit14.58%14.95%
OtherOperating expenses9.76%10.82%
OtherOperating income4.83%4.13%
Cencora, Inc. (GAAP)Gross profit4.26%3.6%
Cencora, Inc. (GAAP)Operating expenses2.93%2.53%
Cencora, Inc. (GAAP)Operating income1.32%1.08%
Cencora, Inc. (Non-GAAP)Adjusted gross profit4.16%3.55%
Cencora, Inc. (Non-GAAP)Adjusted operating expenses2.7%2.23%
Cencora, Inc. (Non-GAAP)Adjusted operating income1.46%1.31%

Income Statement

Nine Months Ended June 30, — (unaudited)

Nine Months Ended June 30, – 2026Nine Months Ended June 30, – 2025Nine Months Ended June 30, – % Change
U.S. Healthcare Solutions2,795,8082,465,54413.4%
International Healthcare Solutions483,805457,0535.9%
Other291,786277,2845.2%
Intersegment eliminations-7,25022
Total segment operating income3,564,1493,199,90311.4%
Gains from antitrust litigation settlements34,184231,011
LIFO credit381,89619,913
Türkiye highly inflationary impact-38,447-36,410
Acquisition-related intangibles amortization-358,642-426,736
Litigation and opioid-related credit (expenses), net160,936-46,263
Acquisition and divestiture-related deal and integration expenses-355,652-190,930
Restructuring and other expenses, net-115,667-140,390
Impairment of assets, including goodwill-249,498
Operating income3,023,2592,610,09815.8%
U.S. Healthcare SolutionsGross profit2.96%2.44%
U.S. Healthcare SolutionsOperating expenses1.69%1.27%
U.S. Healthcare SolutionsOperating income1.27%1.17%
International Healthcare SolutionsGross profit10.61%10.6%
International Healthcare SolutionsOperating expenses8.49%8.41%
International Healthcare SolutionsOperating income2.12%2.19%
OtherGross profit14.98%15.68%
OtherOperating expenses10.45%11.11%
OtherOperating income4.53%4.57%
Cencora, Inc. (GAAP)Gross profit4.12%3.59%
Cencora, Inc. (GAAP)Operating expenses2.91%2.49%
Cencora, Inc. (GAAP)Operating income1.21%1.1%
Cencora, Inc. (Non-GAAP)Adjusted gross profit3.97%3.5%
Cencora, Inc. (Non-GAAP)Adjusted operating expenses2.54%2.15%
Cencora, Inc. (Non-GAAP)Adjusted operating income1.43%1.35%

Balance Sheet

September 30, — (unaudited)

June 30, – 2026September 30, – 2025
Current assets:Cash and cash equivalents2,815,2914,356,138
Current assets:Accounts receivable, net25,448,10525,225,299
Current assets:Inventories21,030,34420,492,480
Current assets:Right to recover assets1,569,2861,625,817
Current assets:Prepaid expenses and other636,051539,339
Current assets:Assets held for sale3,836,060
Current assets:Total current assets55,335,13752,239,073
Current assets:Property and equipment, net2,838,2182,539,076
Current assets:Goodwill and other intangible assets22,446,18017,450,701

Cash Flow

Nine Months Ended June 30, — (unaudited)

Nine Months Ended June 30, – 2026Nine Months Ended June 30, – 2025
Operating Activities:Net income2,972,3211,900,885
Operating Activities:Adjustments to reconcile net income to net cash provided by operating activities81,3561,036,481
Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures:Accounts receivable-754,621-977,608
Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures:Inventories-1,007,059-949,881
Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures:Accounts payable633,382-61,892
Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures:Other, net-237,849-206,282
Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures:Net cash provided by operating activities1,687,530741,703
Investing Activities:Capital expenditures-511,033-418,169
Investing Activities:Cost of acquired companies, net of cash acquired-4,973,696-4,004,220
Investing Activities:Cost of equity investments-28,479-193,792
Investing Activities:Other, net98,843-39,172
Investing Activities:Net cash used in investing activities-5,414,365-4,655,353
Financing Activities:Net debt borrowings 13,729,5563,777,905
Financing Activities:Purchases of common stock-1,000,052-435,471
Financing Activities:Cash dividends on common stock-360,561-329,569
Financing Activities:Employee tax withholdings related to restricted share vesting-105,324-77,674
Financing Activities:Other, net-9,673-2,295
Financing Activities:Net cash provided by financing activities2,253,9462,932,896
Financing Activities:Effect of exchange rate changes on cash, cash equivalents, and restricted cash-25,519-41,800
Financing Activities:Decrease in cash, cash equivalents, and restricted cash, including cash classified within assets held for sale-1,498,408-1,022,554
Financing Activities:Less: Increase in cash classified within assets held for sale-31,184
Financing Activities:Decrease in cash, cash equivalents, and restricted cash-1,529,592-1,022,554
Financing Activities:Cash, cash equivalents, and restricted cash at beginning of period 24,394,5493,297,880
Financing Activities:Cash, cash equivalents, and restricted cash at end of period 22,864,9572,275,326

Cash Flow

Reconciliation of adjusted free cash flowsOperating cash flows$1,687.5M
Reconciliation of adjusted free cash flowsCapital expenditures$(511.0)M
Reconciliation of adjusted free cash flowsFree cash flows$1,176.5M
Reconciliation of adjusted free cash flowsGains from antitrust litigation settlements$(34.2)M
Reconciliation of adjusted free cash flowsAdjusted free cash flows$1,142.3M
Full release

(1) Bolded figures indicate updates to guidance metrics.

(2) For further detail on fiscal 2025 revised reportable segment information, please refer to Exhibit 99.2 to the Company’s Current Report on Form 8-K dated November 5, 2025.⁴

(3) As reported guidance. For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation for investors posted on the Company’s website at investor.cencora.com.

Dividend Declaration

The Company’s Board of Directors declared a quarterly cash dividend of $0.60 per common share, payable August 31, 2026, to stockholders of record at the close of business on August 14, 2026.

Conference Call & Slide Presentation

The Company will host a conference call to discuss its operating results at 8:30 a.m. ET on August 5, 2026. A slide presentation for investors has also been posted on the Company’s website at investor.cencora.com. Participating in the conference call will be:

• Robert P. Mauch, President & Chief Executive Officer

• Eva C. Boratto, Executive Vice President & Chief Financial Officer

The dial-in number for the live call will be +1 (833) 461-5787. From outside the United States and Canada, dial +1 (585) 542-9983. The meeting ID for the call will be 632 369 927. The live call will also be webcast via the Company’s website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.

A replay of the webcast will be posted on investor.cencora.com approximately one hour after the completion of the call and will remain available for one year.

Upcoming Investor Event

Cencora management will be attending the following investor event in the coming months:

• Wells Fargo Healthcare Conference, September 8-10, 2026;

• Morgan Stanley Global Healthcare Conference, September 14-16, 2026; and

• Baird Global Healthcare Conference, September 15, 2026.

Please check the Company website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.

About Cencora

Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #17 on the Global Fortune 500 with more than $300 billion in annual revenue. Learn more at investor.cencora.com⁵

Cencora’s Cautionary Note Regarding Forward-Looking Statements

Certain of the statements contained in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act”). Words such as “aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “on track,” “opportunity,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “sustain,” “synergy,” “target,” “will,” “would” and similar expressions are intended to identify such forward-looking statements, but the absence of these words does not mean the statement is not forward-looking. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially from those indicated is included (i) in the “Risk Factors” and “Management's Discussion and Analysis” sections in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.⁶

CENCORA, INC.

FINANCIAL SUMMARY

(in thousands, except per share data)

(unaudited)

________________________________________¹

Includes a $5.5 million gain from antitrust litigation settlements, a $94.3 million LIFO credit, and Türkiye foreign currency remeasurement expense of $15.4 million in the three months ended June 30, 2026. Includes a $9.5 million gain from antitrust litigation settlements, a $52.1 million LIFO credit, and Türkiye foreign currency remeasurement expense of $14.8 million in the three months ended June 30, 2025.²

Includes a $102.0 million reduction of opioid liability related to the dismissal of opioid litigation in the three months ended June 30, 2026.³

Includes $55.2 million and $37.5 million of adjustments to Retina Consultants of America “RCA” and OneOncology equity units in the three months ended June 30, 2026 and 2025, respectively.⁷⁴... (truncated)n equity method investment’s gain on the sale of a business, a $27.3 million gain on the remeasurement of an equity investment, and a $26.0 million currency remeasurement gain on the deferred tax assets relating to 2020 Swiss tax reform for the three months ended June 30, 2025.⁸

CENCORA, INC.

FINANCIAL SUMMARY

(in thousands, except per share data)

(unaudited)

________________________________________¹

Includes a $34.2 million gain from antitrust litigation settlements, a $381.9 million LIFO credit, and Türkiye foreign currency remeasurement expense of $38.4 million in the nine months ended June 30, 2026. Includes a $231.0 million gain from antitrust litigation settlements, a $19.9 million LIFO credit, and Türkiye foreign currency remeasurement expense of $36.4 million in the nine months ended June 30, 2025.²

Includes a $102.0 million reduction of opioid liability related to the dismissal of opioid litigation and an $86.8 million credit related to a derivative lawsuit settlement in the nine months ended June 30, 2026.³

Includes $152.7 million and $74.9 million of adjustments to RCA and OneOncology equity units in the nine months ended June 30, 2026 and 2025, respectively.⁹⁴

Impairment of assets held for sale, including goodwill, related to our U.S. Consulting Services business, which was divested in April 2026.⁵

In connection with the acquisition of OneOncology, the Company recorded a $1.1 billion gain on the remeasurement of its equity method investment and the extinguishment of the put option liability related to its previously held investment in OneOncology in the nine months ended June 30, 2026.

Includes $39.7 million for the Company’s portion of an equity method investment’s gain on the sale of a business, a $30.6 million gain on the remeasurement of an equity investment, a $15.7 million currency remeasurement gain on the deferred tax assets relating to 2020 Swiss tax reform, and a $35.5 million loss on the divestiture of non-core businesses in the nine months ended June 30, 2025.¹⁰

CENCORA, INC.

GAAP TO NON-GAAP RECONCILIATIONS

(in thousands, except per share data)

(unaudited)

________________________________________¹

Includes a $102.0 million reduction of opioid liability related to the dismissal of opioid litigation.²

Tax reform includes the foreign currency remeasurement of Swiss deferred tax assets arising from 2020 Swiss tax reform and the amortization of those deferred tax assets.

Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release.¹¹

CENCORA, INC.

GAAP TO NON-GAAP RECONCILIATIONS

(in thousands, except per share data)

(unaudited)

________________________________________¹

Represents the Company's portion of an equity method investment's gain on the sale of a business.²

Tax reform includes the foreign currency remeasurement of Swiss deferred tax assets arising from 2020 Swiss tax reform and the amortization of those deferred tax assets.³

The sum of the components does not equal the total due to rounding.

Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release.¹²

CENCORA, INC.

GAAP TO NON-GAAP RECONCILIATIONS

(in thousands, except per share data)

(unaudited)

________________________________________¹

Includes a $102.0 million reduction of opioid liability related to the dismissal of opioid litigation and an $86.8 million credit related to a derivative lawsuit settlement.²

Impairment of assets held for sale, including goodwill, related to our U.S. Consulting Services business, which was divested in April 2026.³

In connection with the acquisition of OneOncology, the Company recorded a gain on the remeasurement of its equity method investment and the extinguishment of the put option liability related to its previously held investment in OneOncology.⁴

Tax reform includes the foreign currency remeasurement of Swiss deferred tax assets arising from 2020 Swiss tax reform and the amortization of those deferred tax assets.

Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release.¹³

CENCORA, INC.

GAAP TO NON-GAAP RECONCILIATIONS

(in thousands, except per share data)

(unaudited)

________________________________________¹

Represents the Company's portion of an equity method investment's gain on the sale of a business.²

Tax reform includes the foreign currency remeasurement of Swiss deferred tax assets arising from 2020 Swiss tax reform and the amortization of those deferred tax assets.³

The sum of the components does not equal the total due to rounding.

Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release.¹⁴

CENCORA, INC.

SUMMARY SEGMENT INFORMATION

(in thousands)

(unaudited)

Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release.¹⁵

CENCORA, INC.

SUMMARY SEGMENT INFORMATION

(in thousands)

(unaudited)

Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release.¹⁶

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Cencora earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.